Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive Investors they're taking some additional time over the new drug application (NDA) for iclaprim as they're keen to make the strongest possible submission to the US regulator.
The next-generation antibiotic has been developed initially to treat acute bacterial skin and skin structure infections and has successfully negotiated two phase III clinical trials.
Meet Wolf Minerals, Thor Mining PLC, Rainbow Rare Earths Limited and Caledonia Mining Corporation at our event,London, 22 March 2018.Register here >>